Filing Flows › ANI Pharmaceuticals (ANIP) › Guidance history
ANI Pharmaceuticals (ANIP) guidance history: what it guided and what it reported
ANI Pharmaceuticals gave guidance in 3 earnings releases on file since May 8, 2026. Its releases raised guidance twice and lowered it once.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.1B–$1.1B (May 8, 2026) → reaffirmed $1.1B–$1.1B (Aug 7, 2026) → lowered $1.1B–$1.1B (Nov 5, 2026) | — | to be reported | — |
Adjusted revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.1B–$1.1B (Aug 7, 2026) | — | to be reported | — |
Adjusted gross margin
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 59.9%–60.9% (May 8, 2026) → reaffirmed 59.9%–60.9% (Aug 7, 2026) → raised 60.3%–61.0% (Nov 5, 2026) | — | to be reported | — |
Adjusted EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $285M–$300M (May 8, 2026) → reaffirmed $285M–$300M (Aug 7, 2026) → raised $290M–$300M (Nov 5, 2026) | — | to be reported | — |
Adjusted EPS
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $9.19–$9.69 (May 8, 2026) → reaffirmed $9.19–$9.69 (Aug 7, 2026) → raised $9.37–$9.71 (Nov 5, 2026) | — | to be reported | — |
The latest quarter
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Questions
Does ANI Pharmaceuticals beat its guidance?
ANI Pharmaceuticals gave guidance in 3 earnings releases on file since May 8, 2026. Its releases raised guidance twice and lowered it once.
How often does ANI Pharmaceuticals raise guidance?
Its earnings releases raised guidance twice and lowered it once since May 8, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.